Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis
The objective of the study is to identify and validate predictive markers of anakinra responsiveness in RA patients by a transcriptomic approach.
Patients with active RA (ACR criteria) were given subcutaneous anakinra (100mg/d) 3 associated with metotrexate. Anakinra efficacy was evaluated at week 12, using the EULAR response criteria.
A blood sample was collected just before the onset of anakinra treatment and total RNAs were extracted from the peripheral blood mononuclear cells. The [33P] radiolabeled mRNAs were hybridized (duplicate or triplicate) over a set of 10.000 human cDNA probes spotted at a high density on nylon membranes. Data were normalized and filtered to allow the comparison between RNA samples. Statistical analyses were performed with the R software and hierarchical clustering was performed with the Cluster and Tree View softwares.
Drug: Response to anakinra associated with methotrexate
|Study Design:||Time Perspective: Prospective|
|Official Title:||Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00213538
|Contact: xavier Le louet, MDfirstname.lastname@example.org|
|CHU de rouen - Hôpitaux de Rouen||Recruiting|
|Rouen, France, 76031|
|Contact: Xavier Le Loët, MD 33 2 32 88 90 19 email@example.com|
|Sub-Investigator: Jean-Philippe Salier, PhD|
|Sub-Investigator: Maryvonne Daveau, MDPhD|
|Sub-Investigator: Thierry Lequerré, MD|
|Sub-Investigator: François TRON, MDPhD|
|Sub-Investigator: Olivier Vittecoq, MDPhD|
|Sub-Investigator: Alain DARAGON, MD|
|Sub-Investigator: Othmane Mejjad, MD|
|Principal Investigator:||Xavier Le Loët||Rouen University Hospital|